Page 646 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

624 PART IV Specific Malignancies in the Small Animal Patient

157. Sjostrom J, Blomqvist C, Mouridsen H, et al.: Docetaxel compared 179. Rissetto K, Villamil JA, Selting KA, et al.: Recent trends in feline
with sequential methotrexate and 5–fluorouracil in patients with intestinal neoplasia: an epidemiologic study of 1,129 cases in the
advanced breast cancer after anthracycline failure: a randomised Veterinary Medical Database from 1964 to 2004, J Am Anim Hosp
VetBooks.ir phase III study with crossover on progression by the Scandinavian 180. Louwerens M, London CA, Pedersen NC, et al.: Feline lymphoma
Assoc 47:28–36, 2011.
Breast Group, Eur J Cancer 35:1194–1201, 1999.
158. Morabito A, Piccirillo MC, Monaco K, et al.: First-line chemo-
2005.
therapy for HER-2 negative metastatic breast cancer patients who in the post-feline leukemia virus era, J Vet Intern Med 19:329–335,
received anthracyclines as adjuvant treatment, Oncologist 12:1288– 181. Gabor LJ, Malik R, Canfield PJ: Clinical and anatomical features of
1298, 2007. lymphosarcoma in 118 cats, Aust Vet J 76:725–732, 1998.
159. Simon D, Schoenrock D, Baumgartner W, et al.: Postoperative 182. Miller MA, Nelson SL, Turk JR, et al.: Cutaneous neoplasia in 340
adjuvant treatment of invasive malignant mammary gland tumors cats, Vet Pathol 28:389–395, 1991.
in dogs with doxorubicin and docetaxel, J Vet Intern Med 20:1184– 183. Overley B, Shofer FS, Goldschmidt MH, et al.: Association
1190, 2006. between ovarihysterectomy and feline mammary carcinoma, J Vet
160. Arenas C, Pena L, Granados-Soler JL, et al.: Adjuvant therapy Intern Med 19:560–563, 2005.
for highly malignant canine mammary tumours: COX-2 inhibi- 184. Skorupski KA, Overley B, Shofer FS, et al.: Clinical characteristics
tor versus chemotherapy: a case-control prospective study, Vet Rec of mammary carcinoma in male cats, J Vet Intern Med 19:52–55,
179:125, 2016. 2005.
161. Marconato L, Lorenzo RM, Abramo F, et al.: Adjuvant gem- 185. Jacobs TM, Hoppe BR, Poehlmann CE, et al.: Mammary adeno-
citabine after surgical removal of aggressive malignant mammary carcinomas in three male cats exposed to medroxyprogesterone
tumours in dogs, Vet Comp Oncol 6:90–101, 2008. acetate (1990–2006), J Feline Med Surg 12:169–174, 2010.
162. de Mello Souza CH, Toledo-Piza E, Amorin R, et al.: Inflamma- 186. Loretti AP, Ilha MR, Ordas J, et al.: Clinical, pathological and
tory mammary carcinoma in 12 dogs: clinical features, cyclooxy- immunohistochemical study of feline mammary fibroepithelial
genase-2 expression, and response to piroxicam treatment, Can Vet hyperplasia following a single injection of depot medroxyprogester-
J 50:506–510, 2009. one acetate, J Feline Med Surg 7:43–52, 2005.
163. Lavalle GE, De Campos CB, Bertagnolli AC, et al.: Canine malig- 187. Mol JA, van Garderen E, Rutteman GR, et al.: New insights in
nant mammary gland neoplasms with advanced clinical stag- the molecular mechanism of progestin-induced proliferation of
ing treated with carboplatin and cyclooxygenase inhibitors, Vivo mammary epithelium:induction of the local biosynthesis of growth
26:375–379, 2012. hormone (GH) in the mammary glands of dogs, cats and humans,
164. Kuntz CA, Dernell WS, Powers BE, et al.: Extraskeletal osteosarco- J Steroid Biochem Mol Biol 57:67–71, 1996.
mas in dogs: 14 cases, J Am Anim Hosp Assoc 34:26–30, 1998. 188. Mol JA, van Garderen E, Selman PJ, et al.: Growth hormone
165. Hermo GA, Turic E, Angelico D, et al.: Effect of adjuvant peri- mRNA in mammary gland tumors of dogs and cats, J Clin Invest
operative desmopressin in locally advanced canine mammary car- 95:2028–2034, 1995.
cinoma and its relation to histologic grade, J Am Anim Hosp Assoc 189. Burrai GP, Mohammed SI, Miller MA, et al.: Spontaneous feline
47:21–27, 2011. mammary intraepithelial lesions as a model for human estrogen
166. Terraube V, Marx I, Denis CV: Role of Von Willebrand factor in receptor- and progesterone receptor-negative breast lesions, BMC
tumor metastasis, Thromb Res 120(suppl 2):S64–70, 2007. Cancer 10(156), 2010.
167. Ripoll GV, Giron S, Krzymuski MJ, et al.: Antitumor effects of 190. Millanta F, Calandrella M, Vannozzi I, et al.: Steroid hormone
desmopressin in combination with chemotherapeutic agents in a receptors in normal, dysplastic and neoplastic feline mammary tis-
mouse model of breast cancer, Anticancer Res 28:2607–2611, 2008. sues and their prognostic significance, Vet Rec 158:821–824, 2006.
168. Egenvall A, Bonnett BN, Haggstrom J, et al.: Morbidity of insured 191. de las Mulas JM, van Niel M, Millan Y, et al.: Immunohistochemi-
Swedish cats during 1999–2006 by age, breed, sex, and diagnosis, cal analysis of estrogen receptors in feline mammary gland benign
J Feline Med Surg 12:948–959, 2010. and malignant lesions: comparison with biochemical assay, Domest
169. Bonnett BN, Egenvall A: Age patterns of disease and death in Anim Endocrinol 18:111–125, 2000.
insured Swedish dogs, cats and horses, J Comp Pathol 142(suppl 192. Martin de las Mulas J, Van Niel M, Millan Y, et al.: Progesterone
1):S33–38, 2010. receptors in normal, dysplastic and tumourous feline mammary
170. Teclaw R, Mendlein J, Garbe P, et al.: Characteristics of pet popu- glands. Comparison with oestrogen receptors status, Res Vet Sci
lations and households in the Purdue Comparative Oncology Pro- 72:153–161, 2002.
gram catchment area, 1988, J Am Vet Med Assoc 201:1725–1729, 193. Meisl D, Hubler M, Arnold S: Treatment of fibroepithelial hyper-
1992. plasia (FEH) of the mammary gland in the cat with the proges-
171. Vascellari M, Baioni E, Ru G, et al.: Animal tumour registry of two terone antagonist aglepristone (alizine), Schweiz Arch Tierheilkd
provinces in northern Italy: incidence of spontaneous tumours in 145:130–136, 2003.
dogs and cats, BMC Vet Res 5(39), 2009. 194. Ordas J, Millan Y, Dios R, et al.: Proto-oncogene HER-2 in nor-
172. Hayden DW, Nielsen SW: Feline mammary tumours, J Small mal, dysplastic and tumorous feline mammary glands: an immuno-
Anim Pract 12:687–698, 1971. histochemical and chromogenic in situ hybridization study, BMC
173. Misdorp W, Romijn A, Hart AA: Feline mammary tumors: a Cancer 7:179, 2007.
case-control study of hormonal factors, Anticancer Res 11:1793– 195. Millanta F, Calandrella M, Citi S, et al.: Overexpression of HER-2
1797, 1991. in feline invasive mammary carcinomas: an immunohistochemical
174. Hayes AA, Mooney S: Feline mammary tumors, Vet Clin North Am survey and evaluation of its prognostic potential, Vet Pathol 42:30–
Small Anim Pract 15:513–520, 1985. 34, 2005.
175. Weijer K, Head KW, Misdorp W, et al.: Feline malignant mam- 196. Winston J, Craft DM, Scase TJ, et al.: Immunohistochemical
mary tumors. I. Morphology and biology: some comparisons detection of HER-2/neu expression in spontaneous feline mam-
with human and canine mammary carcinomas, J Natl Cancer Inst mary tumours, Vet Comp Oncol 3:8–15, 2005.
49:1697–1704, 1972. 197. Rasotto R, Caliari D, Castagnaro M, et al.: An immunohisto-
176. Hayes Jr HM, Milne KL, Mandell CP: Epidemiological features of chemical study of HER-2 expression in feline mammary tumours,
feline mammary carcinoma, Vet Rec 108:476–479, 1981. J Comp Pathol 144:170–179, 2011.
177. Ito T, Kadosawa T, Mochizuki M, et al.: Prognosis of malignant 198. Brodey RS: Canine and feline neoplasms, Adv Vet Sci 24:434,
mammary tumor in 53 cats, J Vet Med Sci 58:723–726, 1996. 1957.
178. Patnaik AK, Liu SK, Hurvitz AI, et al.: Nonhematopoietic neo- 199. Weijer K, Hart AA: Prognostic factors in feline mammary carci-
plasms in cats, J Natl Cancer Inst 54:855–860, 1975. noma, J Natl Cancer Inst 70:709–716, 1983.